Latest news with #NoraPharma
Hamilton Spectator
2 days ago
- Health
- Hamilton Spectator
‘Can lead to serious side effects': Drug recalled in Canada as some bottles may contain wrong pills
Health Canada issued a public advisory after a drug used to treat high blood pressure and chest pain as some bottles of the recalled medication may contain the wrong tablets. One lot of NRA-Amlodipine 5 mg, with the Drug Identification Number (DIN) 02476460, Lot No. EM240229 and expiry date 2027-08, has been impacted by the recall. Nora Pharma has recalled the affected lot of NRA-Amlodipine 5 mg tablets because some bottles may contain the wrong medication, which has been identified as metoprolol succinate prolonged-release 12.5 mg tablets. Health Canada says the correct tablets are white or off-white and octagonal. 'If your bottle contains any round tablets, which are not the correct shape, or if you're unsure, return the bottle to your pharmacy for a replacement,' the agency warns. 'If you are unable to get a replacement immediately, continue to take your medication as directed — but do not take the round tablets as these are the wrong medication.' NRA-Amlodipine tablets are white or off-white, octagonal, flat and scored in the middle with '210' and '5' on one side. The metoprolol succinate prolonged-release 12.5 mg tablets are white, round and scored in the middle. If you are dizzy, have unusually low blood pressure or slow heartbeats, contact your health care provider. 'If you are unable to access a health care professional and you are experiencing these symptoms, call 911,' Health Canada advises. Although metoprolol is also used to treat high blood pressure and chest pain, Health Canada explains substituting amlodipine (5 mg) with metoprolol (12.5 mg) 'can lead to serious side effects' such as dangerous blood pressure changes (especially dangerously low drops), difficulty breathing or an abnormally slow heart rate. Health Canada says patients with other conditions — especially heart failure, asthma, severe peripheral arterial disease, pheochromocytoma or diabetes — and those taking other medications could experience different side effects with varying levels of severity. Children could face a higher risk of serious side effects and potential harm by taking the wrong medication. Health Canada says it's monitoring the company's recall and investigation. You can report a food concern or complaint to the Canadian Food Inspection Agency online. Consumers can report any health or safety incidents related to the use of products by filling out a consumer product incident report form . Report any drug or health product side effects or complaints to Health Canada. You can check for more recall notices published by Health Canada and CFIA online . Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .
Associated Press
7 days ago
- Health
- Associated Press
Public Advisory - NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug
OTTAWA, ON, July 5, 2025 /CNW/ - Summary Affected products Issue Nora Pharma is recalling one lot of NRA-Amlodipine 5 mg tablets because some bottles may contain the wrong tablets, which have been identified as metoprolol succinate prolonged–release 12.5 mg tablets. NRA-Amlodipine treats high blood pressure and chest pain in adults and children aged 6 to 17. The tablets are white or off-white, octagonal, flat, and scored in the middle with '210' and '5' on one side. The metoprolol succinate prolonged-release 12.5 mg tablets are white, round and scored in the middle. While metoprolol is also used to treat high blood pressure and chest pain, substituting amlodipine (5 mg) with metoprolol (12.5 mg) can lead to serious side effects such as dangerous blood pressure changes (especially dangerously low drops), difficulty breathing, or an abnormally slow heart rate. Patients with other conditions (especially heart failure, asthma, severe peripheral arterial disease, pheochromocytoma, or diabetes) and those taking other medications could experience different side effects with varying levels of severity. Children taking the wrong medication may face a higher risk of serious side effects and potential harm. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Additional information for health professionals: Également disponible en français SOURCE Health Canada (HC)
Cision Canada
06-07-2025
- Health
- Cision Canada
Public Advisory - NRA-Amlodipine 5 mg tablets: One lot recalled as some bottles may contain the wrong drug Français
Summary Product: NRA-Amlodipine 5 mg, DIN 02476460 Issue: Health products - Product safety What to do: Check your bottle of NRA-Amlodipine 5 mg tablets. The correct tablets are white or off-white and octagonal. If your bottle contains any round tablets, which are not the correct shape, or if you're unsure, return the bottle to your pharmacy for a replacement. If you are unable to get a replacement immediately, continue to take your medication as directed, but do not take the round tablets as these are the wrong medication. Contact your health care professional if you are dizzy, have unusually low blood pressure or slow heartbeats. If you are unable to access a health care professional and you are experiencing these symptoms, call 911. Affected products Issue Nora Pharma is recalling one lot of NRA-Amlodipine 5 mg tablets because some bottles may contain the wrong tablets, which have been identified as metoprolol succinate prolonged–release 12.5 mg tablets. NRA-Amlodipine treats high blood pressure and chest pain in adults and children aged 6 to 17. The tablets are white or off-white, octagonal, flat, and scored in the middle with '210' and '5' on one side. The metoprolol succinate prolonged-release 12.5 mg tablets are white, round and scored in the middle. While metoprolol is also used to treat high blood pressure and chest pain, substituting amlodipine (5 mg) with metoprolol (12.5 mg) can lead to serious side effects such as dangerous blood pressure changes (especially dangerously low drops), difficulty breathing, or an abnormally slow heart rate. Patients with other conditions (especially heart failure, asthma, severe peripheral arterial disease, pheochromocytoma, or diabetes) and those taking other medications could experience different side effects with varying levels of severity. Children taking the wrong medication may face a higher risk of serious side effects and potential harm. Health Canada is monitoring the company's recall and investigation, including its implementation of corrective and preventive actions to stop this issue from reoccurring. The Department will inform the public if any new health risks are identified. What you should do Check your medication bottle to ensure it only contains NRA-AMLODIPINE 5 mg tablets. If your bottle contains any round tablets, which are not the correct shape, or if you're unsure, return the bottle to your pharmacy for a replacement. If you are unable to get a replacement immediately, continue to take your medication as directed, but do not take the round tablets as these are the wrong medication. Contact your health care professional if you are dizzy, have unusually low blood pressure or slow heartbeats. If you are unable to access a health care professional and you are experiencing these symptoms, call 911. If you have questions about this recall, contact Nora Pharma Inc. by calling their Quality Assurance Department at 450-904-2355 or by emailing [email protected]. Report any health product-related side effects or complaints to Health Canada. Additional information for health professionals: Health care professionals, such as pharmacists, should check packages and bottles labelled NRA-AMLODIPINE 5 mg (amlodipine besylate) before dispensing to make sure they do not contain Metoprolol Succinate prolonged-release 12.5 mg tablets. Report any unusual bottles or other issues to the company and Health Canada.
Associated Press
11-06-2025
- Health
- Associated Press
Sunshine Biopharma Launches Generic Gabapentin for Neuropathic Pain in the Canadian Segment of the Global $1.92 Billion Market
FORT LAUDERDALE, FL / ACCESS Newswire / June 11, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the 'Company'), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched Gabapentin, a new generic prescription drug in the therapeutic class of anticonvulsants. Gabapentin is a generic version of Neurontin®. Gabapentin is an anticonvulsant medication used to treat neuropathic pain and epilepsy. It is also used for the treatment of pain caused by diabetic neuropathy, central pain, and postherpetic neuralgia (a painful condition that can occur after a shingles outbreak). Nora Pharma's Gabapentin is available in strengths of 100 mg, 300 mg, and 400 mg and comes in bottles of 500 capsules. Nora Pharma elected to supply its Gabapentin in capsule format which is the market leader owing to their ease of administration, including in children and the elderly. Gabapentin acts by decreasing the activity of the voltage-dependent calcium channel protein, alpha-2/delta-1. By binding to alpha-2/delta-1, Gabapentin lowers the release of excitatory neurotransmitters and as a result, reduces excess excitation of the neuronal networks in the brain and spinal cord. According to GlobeNewswire, the global Gabapentin market was valued at $1.92 billion in 2024 and is projected to reach $3.07 billion by 2030. The growth in market size for Gabapentin is driven by (i) increasing prevalence of neurological disorders, (ii) expanding applications beyond neuropathic pain and epilepsy, (iii) shift away from the use of opioids for pain management, and (iv) aging population where individuals are more prone to having chronic pain and neurological disorders. Canada represents approximately 1.2% of the global pharmaceutical market for Gabapentin. Despite its relatively small share, Canada is ranked as the eighth-largest pharmaceutical market in the world (Statista). Factors contributing to Canada's prominence in this sector include innovative pharmaceutical sector, aging population, and increasing healthcare expenditures. 'At Sunshine Biopharma, we are unwavering in our commitment to fortifying our presence in Canada's dynamic $9.4 billion generic drugs market, which is forecasted to nearly double to $19.2 billion by 2032,' said Dr. Steve Slilaty, CEO of the Company. 'By steadily expanding our product offerings, investing in research, and maintaining the highest standards of quality, we aim to make a meaningful difference in the lives of patients as we continue to shape the future of affordable medicine.' About Sunshine Biopharma Inc. Sunshine Biopharma currently has 71 generic prescription drugs on the market in Canada and more than 12 additional drugs planned to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancies receiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: All registered trademarks are the property of their respective owners. Safe Harbor Forward-Looking Statements This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the 'Company') that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to the Company's drug development activities, financial performance, and future growth. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings. For more information, please contact: Camille Sebaaly, CFO Direct Line: 514-814-0464 [email protected] SOURCE: Sunshine Biopharma Inc. press release
Associated Press
24-03-2025
- Business
- Associated Press
Sunshine Biopharma Expands Presence in the $53.9 Billion Global Antibiotics Market with the Acquisition of Marketing Rights for Two New Antibiotics in Canada
FORT LAUDERDALE, FL / ACCESS Newswire / March 24, 2025 / Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals today announced that is has signed a strategic agreement granting it the rights to market two new generic antibiotics in Canada. The Company anticipates launching these new products through its wholly-owned Canadian subsidiary, Nora Pharma, in the next six to nine months following regulatory approval. According to BioSpace, the global antibiotics market size in 2024 was estimated at $53.9 billion and is expected to reach approximately $85.8 billion by 2033, representing a compound annual growth rate (CAGR) of 5.3%. In 2023, North America and Europe held the second biggest market share of around 45%. The Canadian portion of this global market is approximately 2.2% or $1.2 billion. 'We believe we are strategically positioned, through Nora Pharma, to introduce these two new antibiotics to the market, complementing our existing portfolio of 70 generic prescription drugs currently on the market in Canada. This expansion signifies a pivotal step in our mission to advance healthcare solutions for our patients,' stated Dr. Steve Slilaty, CEO of Sunshine Biopharma. About Sunshine Biopharma Inc. Sunshine Biopharma currently has 70 generic prescription drugs on the market in Canada and 13 additional drugs scheduled to be launched in the remainder of 2025. Among the new drugs to be launched is NIOPEG®, a biosimilar of NEULASTA®. Like NEULASTA®, NIOPEG® is a long-acting form of recombinant human granulocyte colony-stimulating factor (filgrastim). It is indicated to decrease the incidence of infection in patients with non-myeloid malignancie sreceiving anti-neoplastic therapy. In addition, Sunshine Biopharma is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and (ii) PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. For more information, please visit: All registered trademarks are the property of their respective owners. Safe Harbor Forward-Looking Statements This press release contains forward-looking statements which are based on current expectations, forecasts, and assumptions of Sunshine Biopharma Inc. (the 'Company') that involve risks as well as uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected. These statements appear in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of the Company, including statements related to regulatory approvals, the Company's drug development activities, financial performance, and future growth and product launches. These risks and uncertainties are further described in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC). Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in the Company's filings with the SEC. Reference is hereby made to cautionary statements and risk factors set forth in the Company's most recent SEC filings.
